Publications

Adult height is associated with risk of cancer and mortality in 5.5 million Swedish women and men
Benyi E, Linder M, Adami J, Kieler H, Palme M, Sävendahl L
Journal of epidemiology and community health 2019;():-

Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden
Vinter N, Linder M, Andersen M, Pedersen Ab, Madsen M, Schachterle Se, et al
Pharmacoepidemiology and drug safety 2019;():-

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
Löfling L, Sundström A, Kieler H, Bahmanyar S, Linder M
Clinical epidemiology 2019;11():133-143

Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts
Ekstrand C, Linder M, Baricault B, Lafaurie M, Sailler L, Lapeyre-mestre M, et al
Thrombosis research 2019;178():124-131

Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany
Castellsague J, Poblador-plou B, Giner-soriano M, Linder M, Scholle O, Calingaert B, et al
Pharmacoepidemiology and drug safety 2018;27(9):953-961

Influence of statin potency on the risk of renal failure-A nationwide cohort study using laboratory data
Citarella A, Linder M, Cammarota S, Sundstrom A, Kieler H
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2018;:349-349

Methods for estimating treatment episodes-Dosage assumptions versus real prescribed dosage accounting for treatment gaps and overlaps
Pazzagli L, Brandt L, Linder M, Sundstrom A, Vago E, Myers D, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2018;:162-162

Methods for time-varying exposure related problems in pharmacoepidemiology: An overview
Pazzagli L, Linder M, Zhang M, Vago E, Stang P, Myers D, et al
Pharmacoepidemiology and drug safety 2018;27(2):148-160

Methods for time-varying exposure related problems in pharmacoepidemiology: An overview (vol 27, pg 148, 2018)
Pazzagli L, Linder M, Zhang M
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2018;27(3):356-

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
Margulis Av, Linder M, Arana A, Pottegård A, Berglind Ia, Bui Cl, et al
PloS one 2018;13(9):e0204456-

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study
Strongman H, Christopher S, Majak M, Williams R, Bahmanyar S, Linder M, et al
BMJ open diabetes research & care 2018;6(1):e000481-

Risk of hypertension in patients treated with mirabegron compared with tolterodine: A nationwide cohort study
Citarella A, Linder M, Cammarota S, Kieler H
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2018;:281-281

Young patients with risk factors prevalent in the elderly - differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers
Hajiebrahimi M, Linder M, Hägg D, Berglind Ia, Mcelligott S, Valgardsson Vs, et al
Clinical epidemiology 2018;10():705-715

A Population-Based Cohort Study to Assess the Potential Association Between Latanoprost Use and Primary Ocular Melanoma and Facial Cutaneous Melanoma
George P, Kieler H, Berglind I, Linder M, Hagg D, Xu Wn, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:266-267

Bias Due to Selective Inclusion of Variables, Not Related to the Exposure nor to the Outcome, into a Propensity Score Model - A Simulation Study
Karlsson P, Linder M
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:89-90

Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany
Castellsague J, Perez-gutthann S, Calingaert B, Bui C, Varas-lorenzo C, Arana A, et al
Pharmacoepidemiology and drug safety 2017;26(6):615-624

Demographics and Prevalence of Comorbidities for Patients with Mild, Moderate, and Severe Psoriasis
Hajiebrahimi M, Sundstrom A, Hagg D, Mcelligott S, Valgardsson S, Villacorta R, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:379-380

Impact of Risk Minimization Measures on the Use of Cilostazol in Europe
Castellsague J, Calingaert B, Poblador-plou B, Giner-soriano M, Linder M, Scholle O, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:428-429

Methods for Time-Varying Exposure-Related Problems in Pharmacoepidemiolgy: A Literature Overview
Pazzagli L, Linder M, Zhang Ml, Vago E, Stang P, Myers D, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:87-88

Nested Case-Control Studies to Assess the Association Between Pioglitazone Use and Bladder Cancer Risk in a Swedish Type 2 Diabetes Cohort
Olmastroni E, Bahmanyar S, Linder M
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:549-550

Palivizumab Exposure and the Risk of Atopic Dermatitis, Asthma and Allergic Rhinoconjunctivitis: A Cross-National, Population-Based Cohort Study
Haerskjold A, Stokholm L, Linder M, Thomsen Sf, Bergman G, Berglind Ia, et al
Paediatric drugs 2017;19(2):155-164

Pharmacological agents preceding a diagnosis of immune thrombocytopenia in adult patients developing the chronic form: A Swedish national register study
Löfling L, Linder M, Ekstrand C, Cherif H, Kieler H, Bahmanyar S
Thrombosis research 2017;160():27-31

Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study
Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, et al
BMJ open diabetes research & care 2017;5(1):e000364-

Post-Authorization Safety Study of the Utilization of Apixaban in Sweden
Linder M, Schachterle Se, Ataher Q, Andersen M
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:567-567

Treatment Patterns in Primary Chronic Immune Thrombocytopenia Patients
Ekstrand C, Linder M, Cherif H, Kieler H, Bahmanyar S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2017;:572-572

Cancer Risk in Users of Antimuscarinic Drugs for Overactive Bladder: A Cohort Study in the Swedish National Registers
Linder M, Margulis Av, Anveden-berglind I, Bahmanyar S, Bui Cl, Atsma Wj, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:535-535

Cardiovascular Risk in Users of Antimuscarinic Drugs for Overactive Bladder: A Cohort Study in the Swedish National Registers
Linder M, Margulis Av, Anveden-berglind I, Bahmanyar S, Bui Cl, Atsma Wj, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:493-493

Characteristics of Patients at Initiation of Treatment for Primary Chronic Immune Thrombocytopenia
Ekstrand C, Linder M, Cherif H, Kieler H, Bahmanyar S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:197-197

Characterization of New Users of Cilostazol in the United Kingdom, Spain, Sweden, and Germany
Castellsague J, Calingaert B, Poblador-plou B, Giner-soriano M, Linder M, Scholle O, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:203-204

General Pharmacological Treatments Preceding A Primary Chronic Immune Thrombocytopenia Diagnosis
Lofling L, Linder M, Ekstrand C, Cherif H, Kieler H, Bahmanyar S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:645-646

Increased susceptibility to infections before the diagnosis of immune thrombocytopenia
Ekstrand C, Linder M, Cherif H, Kieler H, Bahmanyar S
Journal of thrombosis and haemostasis : JTH 2016;14(4):807-14

Infection and Anti-Infective Treatment Preceding a Diagnosis of Primary Persisting Immune Thrombocytopenia
Sohrabian D, Linder M, Ekstrand C, Cherif H, Kieler H, Bahmanyar S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:88-88

Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence
Citarella A, Linder M, Kieler H, Berglind Ia, Sundström A, Wettermark B, et al
European journal of clinical pharmacology 2016;72(3):349-57

Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study
Haerskjold A, Linder M, Henriksen L, Thomsen Sf, Kieler H, Ravn H, et al
Paediatric drugs 2016;18(6):435-441

Patterns of Use of Antimuscarinic Drugs to Treat Overactive Bladder in Denmark, Sweden and the United Kingdom
Margulis Av, Linder M, Arana A, Pottegard A, Anveden-berglind I, Bui Cl, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2016;:654-655

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries
Korhonen P, Heintjes Em, Williams R, Hoti F, Christopher S, Majak M, et al
BMJ (Clinical research ed.) 2016;354():i3903-

Children with hemodynamically significant congenital heart disease can be identified through population-based registers
Bergman G, Hærskjold A, Stensballe Lg, Kieler H, Linder M
Clinical epidemiology 2015;7():119-27

Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins
Berglind Ia, Andersen M, Citarella A, Linder M, Sundström A, Kieler H
Menopause (New York, N.Y.) 2015;22(4):369-76

Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in Danish and Swedish children
Henriksen L, Simonsen J, Haerskjold A, Linder M, Kieler H, Thomsen Sf, et al
The Journal of allergy and clinical immunology 2015;136(2):360-6.e2

Increased Anti-infective Treatments Preceding a Diagnosis of Primary Immune Thrombocytopenia
Ekstrand C, Linder M, Cherif H, Kieler H, Bahmanyar S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2015;:411-412

Preliminary Results of Bladder Cancer Risk in Relation to Exposure to Pioglitazone Among Patients with T2DM in the Pan European Multi-database Bladder Cancer Risk Characterisation Study
Korhonen P, Heintjes Em, Williams R, Hoti F, Christopher S, Majak M, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2015;:31-32

Susceptibility to Infection before Diagnosis of Primary Chronic Immune Thrombocytopenia
Ekstrand C, Linder M, Cherif H, Kieler H, Bahmanyar S
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2015;:519-519

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register - implications for register-based drug studies
Linder M, Byström C, Kieler H, Bergman G, Haerskjold A
Clinical epidemiology 2015;7():45-51

Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure
Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H
Inflammatory bowel diseases 2014;20(6):1091-8

Family history of cardiovascular disease and influence on statin therapy persistence
Citarella A, Kieler H, Sundström A, Linder M, Wettermark B, Berglind Ia, et al
European journal of clinical pharmacology 2014;70(6):701-7

Palivizumab exposure in early childhood and risk of atopic disease
Haerskjold A, Henriksen L, Linder M, Thomsen Sf, Bergman G, Berglind Ia, et al
ALLERGY 2014;:100-100

Risks of malignant and non-malignant tumours in tall women treated with high-dose oestrogen during adolescence
Benyi E, Kieler H, Linder M, Ritzén M, Carlstedt-duke J, Tuvemo T, et al
Hormone research in paediatrics 2014;82(2):89-96

Validation of the Use of the ICD-10 Diagnostic Code for Irritable Bowel Syndrome in the Swedish National Patient Register
Jossan N, Backman As, Linder M, Altman M, Simren M, Olen O, et al
GASTROENTEROLOGY 2014;146(5):S543-S543

Menopausal Hormone Therapy and Risks of Cardiovascular Events and Mortality in Female Statin Users - A Population Based Register Study
Berglind Ia, Linder M, Citarella A, Andersen M, Kieler H
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2013;:365-365

Persistence with Statin Therapy: Does Family History of Cardiovascular Events Influence Medication-Taking Behaviour?
Citarella A, Kieler H, Sundstrom A, Linder M, Wettermark B, Berglind Ia, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2013;:19-19

Persistence with Statin Therapy: Does the Level of Lipid Values Influence Medication-Taking Behaviour?
Citarella A, Kieler H, Sundstrom A, Linder M, Wettermark B, Berglind Ia, et al
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2013;:385-386

Risk of Preterm Delivery in Women with Inflammatory Bowel Disease - Effects of Disease Activity and Drug Exposure
Broms G, Linder M, Granath F, Stephansson O, Elmberg M, Kieler H
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2013;:144-144

Complications from inflammatory bowel disease during pregnancy and delivery
Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2012;10(11):1246-52

Inflammatory Bowel Disease in Pregnancy and Thrombophilic Disorders - Impact of Type of Disease and Treatment
Broms G, Linder M, Granath F, Elmberg M, Stephansson O, Kieler H
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 2012;:15-15

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden
Grönhagen Cm, Fored Cm, Linder M, Granath F, Nyberg F
The British journal of dermatology 2012;167(2):296-305

New modes of data partitioning based on PARS peak alignment for improved multivariate biomarker/biopattern detection in H-1-NMR spectroscopic metabolic profiling of urine
Torgrip Rjo, Lindberg J, Linder M, Karlberg B, Jacobsson Sp, Kolmert J, et al
METABOLOMICS 2006;2(1):1-19

Precision of prediction in second-order calibration, with focus on bilinear regression methods
Linder M, Sundberg R
JOURNAL OF CHEMOMETRICS 2002;16(1):12-27

Second-order calibration: bilinear least squares regression and a simple alternative
Linder M, Sundberg R
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS 1998;42(1-2):159-178

Show all publications